Elevation Oncology Gets FDA Fast-Track Designation for EO-3021
By Colin Kellaher
Elevation Oncology has won Food and Drug Administration fast-track designation for EO-3021, its lead drug candidate, in certain patients with gastrointestinal cancers.
Elevation on Monday said the designation covers EO-3021 in adults with advanced or metastatic gastric and gastroesophageal junction cancer expressing the marker protein Claudin 18.2 that has progressed on or after prior therapy.
The FDA's fast-track program is designed to facilitate the development and expedite the review of treatments for serious or potentially life-threatening illnesses with high unmet medical needs.
Elevation, a Boston oncology company, is studying EO-3021 in a Phase 1 trial in patients with advanced, unresectable or metastatic solid tumors likely to express Claudin 18.2.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 23, 2024 08:12 ET (12:12 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now
-
10 Undervalued Wide-Moat Stocks
-
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
-
New 4-Star Stocks
-
Intel Fair Value Left Unchanged Despite Qualcomm Takeover Talk
United States